glp 1 gip receptor agonist The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Science Behind GLP 1 GIP
Description
E., Lavell, J., and Foreman, R
[DOI] [PMC free article] [PubMed] [Google Scholar] 69.Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB
This article explores the biology of GLP-1, reviews current and emerging therapies, and examines their implications for the future of drug discovery and development
But used wisely, with resistance training, protein optimisation, and patient selection, they may represent the most significant advance in cardiometabolic medicine since statins
JH: Conceptualization, Funding acquisition, Visualization, Writing review and editing
